Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03061812 · ClinicalTrials.gov registry record · Phase 3
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
NCT03061812 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 444 participants.
The verdict
NCT03061812, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
Study Summary
The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line platinum-based chemotherapy.
Interventions
- DRUG Dexamethasone
- DRUG Topotecan
- DRUG Rovalpituzumab tesirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2020-02-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03061812
The ClinicalTrials.gov registry entry for NCT03061812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03061812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03061812 about?
NCT03061812 is a clinical study titled "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)". The purpose of this randomized, open-label, 2-arm, phase 3 study is to assess the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan in participants with advanced or metastatic SCLC with high levels of DLL3, who have first disease progression during or following front-line...
What is the current status of trial NCT03061812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2017-04-11. Estimated completion is 2020-02-12.
What interventions are being tested in trial NCT03061812?
The interventions under investigation include: Dexamethasone (DRUG), Topotecan (DRUG), Rovalpituzumab tesirine (DRUG).
Who is sponsoring clinical trial NCT03061812?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.